

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA: Obinutuzumab in combination with bendamustine for treating rituximab-refractory follicular lymphoma

Batch 43

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Attendees at the scoping workshop noted that people from some religious groups are unwilling to have treatment with stem cell transplants, and that for some people a matched stem cell transplant cannot be found. Attendees at the scoping workshop considered that it is unlikely that obinutuzumab in combination with bendamustine will be considered in people for whom a stem cell transplant is appropriate. Therefore there is no equalities issue.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The population in this scope does not exclude people who are unable or are unwilling to have a stem cell transplant, and no subgroups based on the suitability of stem cell transplant are included. Consequently, no groups are excluded from consideration, and there is no equalities issue.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes to the scope are needed.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders have been identified.

Approved by Associate Director (name):Janet Robertson.....

Date: 16 March 2016